Dr. Daniel Almquist, MD

Dr. Almquist practices at Sanford Fargo Hospice in Fargo, North Dakota.

Dr. Almquist's NPI, 1134533805, was assigned on June 20, 2014. Dr. Almquist holds North Dakota license 17485.

Dr. Almquist's primary practice is Sanford Fargo Hospice, at 801 Broadway North, Fargo, ND 58102 in Cass County. The practice phone is (701) 234-7550.

Dr. Almquist's primary practice is Sanford Fargo Hospice in Fargo, North Dakota. Dr. Almquist is also affiliated with Sanford Broadway Medical Center. The medical group on file is Sanford West Fargo Clinic. Dmand AI also links Dr. Almquist to 4 more hospitals, 2 group practices and clinics, 1 hospice and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Almquist practices, 9 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Almquist's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Almquist's licenses on file in 3 states: North Dakota, Arizona and Nebraska.

CMS data shows 1,189 Medicare services from Dr. Almquist across 6 procedure codes in 2024, for 269 Medicare patients. Medicare paid $61,688 for them.

CMS counts 269 Medicare patients who saw Dr. Almquist in 2024. The largest group is 65 to 74, with 125 patients. 74% of them have high blood pressure, and 72% have high cholesterol. 9% are also on Medicaid. Their average risk score is 2.17, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Almquist's median patient age at 72, with 53% women.

In 2024, Dr. Almquist wrote 1,416 Medicare Part D claims for 194 patients. 80% of them were for generic drugs. CMS names the drug for 1,101 of them, across 41 drugs with 11 or more claims each, at $1,142,479 in total drug cost. In 2023, CMS named 749 claims across 24 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Almquist for performance year 2024, reported as part of a group. Dr. Almquist accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Almquist as offering telehealth.

Dmand AI links 17 papers to Dr. Almquist, published from 2019 to 2023. 2020 was the busiest year, with 6. The most frequent topics are Lung Neoplasms, Small Cell Lung Carcinoma and Carcinoma, Non-Small-Cell Lung. Dr. Almquist has published most often in JCO Oncol Pract. Dr. Almquist's most frequent co-authors are Vinicius Ernani, Mohamad Bassam Sonbol, MD and Thorvardur R. Halfdanarson, MD.

CMS Open Payments shows 19 general payments to Dr. Almquist from 5 drug and device companies from 2019 to 2025. Travel and lodging make up the largest share, 51% of the total. Penumbra, Inc. paid the most, $313.